Hadassah Medical Center

Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

Retrieved on: 
Wednesday, December 28, 2022
Clinical trial, Clinical Cancer Research, Multiple myeloma, AL amyloidosis, Neurotoxicity, BCMA, Hematopoietic stem cell transplantation, European Society for Primary Immunodeficiencies, MD, Hadassah Medical Center, Blood, European Hematology Association, ORR, CAR, CRS, Patient, Learning, Manuscript, CART, Amyloidosis, AL, Pharmaceutical industry, Dentistry, Immunotherapy

“We are delighted to be presenting additional clinical data at the upcoming at European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting,” said Polina Stepensky, MD, Director of the Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator.

Key Points: 
  • “We are delighted to be presenting additional clinical data at the upcoming at European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting,” said Polina Stepensky, MD, Director of the Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator.
  • NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients as of the February 26, 2022 AL Amyloidosis manuscript publication date.
  • In addition, zero neurotoxicity of any grade was observed and zero events of immune effector cell-associated neurotoxicity syndrome (ICANs) were observed with NXC-201 treatment.
  • These data were published in Haematologica https://doi.org/10.3324/haematol.2022.281628 (multiple myeloma) and Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 (AL amyloidosis).

Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

Retrieved on: 
Wednesday, December 28, 2022
Clinical trial, Clinical Cancer Research, Multiple myeloma, AL amyloidosis, Neurotoxicity, BCMA, Hematopoietic stem cell transplantation, MD, European Society for Primary Immunodeficiencies, Blood, Hadassah Medical Center, European Hematology Association, ORR, CAR, CRS, Patient, Learning, AL, Manuscript, CART, Amyloidosis, Dentistry, Pharmaceutical industry, Immunotherapy

“We are delighted to be presenting additional clinical data at the upcoming at European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting,” said Polina Stepensky, MD, Director of the Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator.

Key Points: 
  • “We are delighted to be presenting additional clinical data at the upcoming at European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting,” said Polina Stepensky, MD, Director of the Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator.
  • NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients as of the February 26, 2022 AL Amyloidosis manuscript publication date.
  • In addition, zero neurotoxicity of any grade was observed and zero events of immune effector cell-associated neurotoxicity syndrome (ICANs) were observed with NXC-201 treatment.
  • These data were published in Haematologica https://doi.org/10.3324/haematol.2022.281628 (multiple myeloma) and Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 (AL amyloidosis).

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 4, 2023
Hebrew University of Jerusalem, CXCR4, Security (finance), Neurodegeneration, Immunotherapy, TASE, Patient, Multiple myeloma, Novartis, Drug development, COVID-19, Medicine, FDA, Bachelor of Medical Sciences, Pancreatic cancer, PDUFA, Psychiatry, PDAC, Therapy, NDA, Cancer, Drug, Annual report, TEL, Risk, Hadassah Medical Center, Pharmaceutical industry, BioLineRx

TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.  Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions.  Her appointment is effective today, January 4, 2023.

Key Points: 
  • TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.
  • "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx.
  • "I am very excited to be joining a dedicated team focused on bringing best-in-class therapeutics to patients with cancers and to other diseases with significant unmet need," said Tami Rachmilewitz, M.D., Chief Medical Officer at BioLineRx.
  • "I look forward to supporting our clinical and medical teams and working with my fellow leaders at BioLineRx to realize the broad potential of our programs."

Dr. Hananel Holzer joins The Fertility Partners team as Medical Director, Third-Party Reproduction and Education

Retrieved on: 
Tuesday, November 29, 2022
Family, Health, Consumer, Other Health, Baby, Maternity, General Health, Defense Department Advisory Committee on Women in the Services, Fertility, Reproductive endocrinology and infertility, Science, IVF, Gynaecology, Infertility, Reproductive medicine, Hadassah Medical Center, Associate, Patient, McGill University Health Centre, TFP, Egg, Committee, Education, Obstetrics, Medical director, McGill University, ART, Assisted reproductive technology, Publication, Division, Pregnancy, Reproduction, Person, Medical device, Birth control, Medicine

The Fertility Partners (TFP), a network of leading fertility practices across North America, today announced the appointment of Dr. Hananel Holzer MD, in the newly created role as Medical Director of Third-Party Reproduction and Education.

Key Points: 
  • The Fertility Partners (TFP), a network of leading fertility practices across North America, today announced the appointment of Dr. Hananel Holzer MD, in the newly created role as Medical Director of Third-Party Reproduction and Education.
  • Dr. Holzer will lead the evolution of a range of programs delivered through TFP partner clinics to support all persons involved in third-party reproduction.
  • In addition to his role at TFP, Dr. Holzer will be a member of the practice team at TFP partner clinic ReproMed Fertility.
  • In addition to third party reproduction, Dr. Holzers main interests are fertility preservation and a comprehensive team approach to infertility related issues.

Breakthrough RNA-Based Anti-Cancer Immunotherapy Treatments Being Developed by Global Consortium led by the Hadassah Cancer Research Institute

Retrieved on: 
Monday, September 19, 2022
Wolf Prize, Bioinformatics, Therapy, Safety, Molecular biology, Melanoma, MD, RNA transfection, Center, Faculty of Pharmacy, University of Lisbon, University, University of Erlangen–Nuremberg, Hebrew language, HCRI, Biochemistry, Hadassah Medical Center, Immunotherapy, Neoplasm, Cancer, Physician, Cancer epigenetics, Free University of Brussels (1834–1969), Goal, Biocomputing, Acute myeloid leukemia, Uveal melanoma, Centre for Genomic Regulation, Bar-Ilan University, RNA, Research, RNA splicing, Immune system, Pharmaceutical industry, Vaccine, Dietary supplement, Merck, Biobank

JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.

Key Points: 
  • JERUSALEM, Sept. 19, 2022 /PRNewswire/ -- The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today that it is leading CancerRNA ( www.cancerna.info ), a global consortium that aims to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses.
  • While RNA-based therapies, namely mRNA vaccines, shined during the pandemic and saved millions of lives, they have yet to be successfully tested in cancer therapies.
  • About the Hadassah Cancer Research Institute:
    Hadassah Cancer Research Institute (HCRI) is a translational research arm of Hadassah Medical Organization and Sharett Cancer Center in Jerusalem.
  • For additional information on the Hadassah Cancer Research Institute and CanceRNA, contact:

BioNTech CEO Ugur Sahin Visited Israel to Discuss Cooperation on Pandemic Preparedness and the Development of Innovative Medicines

Retrieved on: 
Wednesday, September 7, 2022
Hebrew University of Jerusalem, COVID-19, Regeneron Pharmaceuticals, Public health, CEO, Ministry, Cancer, Research, Epidemic, Ministry of Economy (Spain), Ministry of Health (Bahrain), Israel Innovation Authority, Private Securities Litigation Reform Act, Vaccine, BioNTech, Infection, Hoffmann-La Roche, SEC, Accountant, Nasdaq, Company, Therapy, Immunotherapy, Form, Ministry of Finance (Israel), Weizmann Institute of Science, Hadassah Medical Center, RNA transfection, BNTX, Viktor Genev, Pharmaceutical industry, Pfizer, Industry, Genentech, Health

The visit was set to promote the potential cooperation between the State of Israel, its academic institutions and BioNTech on pandemic preparedness and discuss potential research collaborations aimed at developing innovative medicines.

Key Points: 
  • The visit was set to promote the potential cooperation between the State of Israel, its academic institutions and BioNTech on pandemic preparedness and discuss potential research collaborations aimed at developing innovative medicines.
  • In addition, the discussions also included the possibility of the establishment of a research and production facility in Israel.
  • Prof. Sahin also held a lecture at the Weizmann Institute on the potential of mRNA vaccines and therapeutics.
  • Orna Barbivay, Minister of Economy and Industry of Israel, said: Israel works to find technological solutions to epidemics and diseases.

xCAT IQ Installed at Hadassah University Hospital

Retrieved on: 
Thursday, September 1, 2022
Hebrew University of Jerusalem, University, IQ, Fracture, 3D, Bed, DDS, Oral, ANN, Rothschild, Eleazar Sukenik, World Zionist Organization, Oral and maxillofacial surgery, Bone fracture, CT, Hebrew language, Department, Human, Hospital, Multimedia, Cone beam computed tomography, MD, Cholesteatoma, Surgeon, High-dependency unit, Paola Lattus, School, Hadassah Medical Center, XCAT, Prophet, Street of the Prophets, MS, Otorhinolaryngology, Dentistry, Patient, Medical imaging, Health, DMD, Hadassah Women's Zionist Organization of America

Xoran's xCAT IQ is a truly mobile cone beam CT system for soft tissue and bone imaging.

Key Points: 
  • Xoran's xCAT IQ is a truly mobile cone beam CT system for soft tissue and bone imaging.
  • With high resolution down to 70 microns and an extremely small footprint, the xCAT IQ is uniquely suited to meet the needs of the Hadassah clinicians.
  • The implementation of xCAT IQ was largely facilitated by the efforts of Prof. Yoram Weiss, MD, Director General of the Hadassah Medical Organization.
  • Since the establishment of Hadassah's first hospital on Jerusalem's Neviim Street (Street of the Prophets) - a gift of the Rothschild family in 1918 - the Hadassah University Medical Center has expanded to include two University hospitals in Jerusalem - located on Mt.

Prof. Zelig Tochner Tells How To Install Proton Therapy in Existing Radiation Linac Vaults

Retrieved on: 
Tuesday, August 30, 2022
Proton, University, 3D, Cancer, Synchrotron, Arm, Trial of the century, Solution, CT, Proton therapy, Hebrew language, Steven Naifeh, Orientation, Radiation therapy, Hadassah Medical Center, National University of Singapore, MD, Philadelphia, Hospital, TEL, FDA, Neutron, Oncology, ROI, PBS, TPS, CE, National university, Acquisition, Einstein Medical Center Philadelphia, Patient, Medical imaging, Radiation

TEL AVIV, Israel, Aug. 30, 2022 /PRNewswire-PRWeb/ -- Despite the proven and potential clinical benefits of proton therapy, this treatment is currently available to very few patients. The reasons are primarily economic. Until now, the equipment size required its own dedicated building. Combining construction and heavy equipment cost severely limited the potential for cost-effective operation and ROI in a reasonable period. Previously, the dimension of proton therapy equipment – accelerator, beam delivery, treatment planning and delivery room -- did not allow for integration of the equipment within existing radiotherapy practice facilities. Because of the constraints of legacy equipment and design, combined with the substantial cost to develop, build and operate a stand-alone proton center, the expansion of proton treatment to existing radiotherapy centers, and to physician-owned centers, has been extremely limited.

Key Points: 
  • Despite all of the above, due to the clinical benefits demonstrated since 1954, proton therapy has become a significant tool to fight cancer with radiation.
  • Proton therapy can now be centered in an existing linac vault.
  • To do so, there are five requirements to allow healthcare provider to integrate proton therapy into an operating radiotherapy department, while eliminating the barriers of installing and operating existing legacy proton therapy systems.
  • A Professor Emeritus and the former medical director of the Roberts Proton Therapy Center at the University of Pennsylvania Medical Center, one of the world's largest proton therapy facilities.

Asher Bio Appoints Independent Director Bob Deresiewicz, M.D., to its Board

Retrieved on: 
Wednesday, July 6, 2022
Biotechnology, Pharmaceutical, Health, Cell, Self-signed certificate, Wellington Management Company, Board of directors, Science, LinkedIn, Biotechnology, Hadassah Medical Center, LLP, Infectious Diseases Society of America, Harvard Medical School, Internal medicine, Infection, Columbia University, Cancer, Division, Harvard Business School, Degenerative disease, Third Rock Ventures, American College of Physicians, Toxicity, Tropical medicine, Physician, Autoimmune disease, Columbia University Irving Medical Center, Medicine, Medical Center, Board, American College, Icahn School of Medicine at Mount Sinai, Vaccine, Biochemistry, Brigham

Asher Biotherapeutics , Inc. (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders, today announced the appointment of Bob Deresiewicz, M.D., to its Board of Directors.

Key Points: 
  • Asher Biotherapeutics , Inc. (Asher Bio), a biotechnology company developing precisely-targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders, today announced the appointment of Bob Deresiewicz, M.D., to its Board of Directors.
  • Bob is an outstanding addition to our Board of Directors.
  • Asher Bio is a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders.
  • Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.

P-Cure to support Hadassah Medical Organization in being the first to provide Proton Therapy to cancer patients in Israel

Retrieved on: 
Tuesday, June 28, 2022
Proton, TEL, FDA, Hadassah Medical Center, Patient, Eleazar Sukenik, Asian Pacific Development Center, Head, Travel, Brain, Hebrew University of Jerusalem, Cancer, Ministry, Neck, Proton therapy, CE, Neoplasm, Radiation, Physician, Ethics committee, Medical imaging, Health, Hadassah Women's Zionist Organization of America

TEL AVIV, Israel, June 28, 2022 /PRNewswire-PRWeb/ -- P-Cure Ltd. ("P-Cure"), the provider of the most compact 360° gantry-less adaptive proton therapy system that can be installed in a linac vault, announced today a collaboration with Hadassah Medical Organization ("Hadassah") in Jerusalem. The collaboration will provide cancer patients in Israel with access to proton therapy, the most targeted type of radiation therapy. The treatments will be carried out as a clinical research initiative with no economic burden to patients or medical insurers.

Key Points: 
  • The collaboration will provide cancer patients in Israel with access to proton therapy, the most targeted type of radiation therapy.
  • The treatments will be performed by the medical team of Hadassah at the P-Cure Clinical Research and Development Center.
  • Until now the patients in Israel, who were found eligible for proton therapy, have to travel abroad.
  • Proton therapy has proven its clinical benefits since the first hospital-based proton center started treating patients 32 years ago.